Aug 25 2023 This Week in Cardiology

GLP-1 agonists in HFpEF, DOACs for subclinical AF, renal denervation, and the matter of remaining in the profession are the topics John Mandrola, MD, discusses in this week's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I. Obesity and HFpEF

GLP-1 Agonists in HFpEF With Obesity: Are We There Yet? https://www.medscape.com/viewarticle/993980

Wegovy Scores HFpEF Benefits in People With Obesity https://www.medscape.com/viewarticle/995844

- Semaglutide in Obese Patients With HFpEF https://www.nejm.org/doi/full/10.1056/NEJMoa2306963

- Rationale/Protocol Paper https://doi.org/10.1016/j.jchf.2023.05.010

II. DOAC for Subclinical AF

- NOAH-AFNET 6 Rationale/Protocol https://doi.org/10.1016/j.ahj.2017.04.015

- NOAH-AFNET 6 Trial Results https://www.nejm.org/search?q=NOAH+AFNET

III. Renal Denervation

ReCor Renal Denervation System Safe, Effective: FDA Panel https://www.medscape.com/viewarticle/995741

FDA Panel Split on Efficacy of Spyral Renal Denervation https://www.medscape.com/viewarticle/995800

SPYRAL HTN-ON MED https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00455-X/fulltext

IV. Maintenance of Certification

As MOC Debate Heats Up, Cardiology Societies Weigh In https://www.medscape.com/viewarticle/moc-debate-heated-cardiology-societies-weigh-2023a1000jju

Features

Mandrola's 5 Things to Look for at the Upcoming ESC 2023

https://www.medscape.com/viewarticle/995614

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

https://www.medscape.com/features/public/machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact: [email protected]